Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer

• Published in: BMC cancer Vol. 24; no. 1; p. 67
• Main Authors: Fan, Mengjiao, Deng, Guochao, Ma, Yue, Si, Haiyan, Wang, Zhikuan, Dai, Guanghai
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.01.2024; BioMed Central; BMC
• Subjects: Adenocarcinoma; Antimitotic agents; Antineoplastic agents; Big Data; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Development and progression; Diagnosis; Dosage and administration; Gemcitabine; Hospitals; Immunotherapy; Irinotecan; Medical prognosis; Metastases; Metastasis; Mortality; New chemotherapy regimens; Oxaliplatin; Paclitaxel; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Patient outcomes; Patients; Prognosis; Software; Survival; Survival analysis; Treatment landscape; Treatment patterns; Treatment sequences; China; Irinotecan; FOLFIRINOX; New chemotherapy regimens; Pancreatic ductal adenocarcinoma; Treatment patterns; Treatment landscape; Treatment sequences; Nab-paclitaxel
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-11823-8

Despite some therapeutic advances, improvement in survival rates of unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDAC) has been minimal over recent decade. We aimed to evaluate the impact of different treatment sequences on clinical outcomes of advanced PDAC at our academic institution. In this single institution retrospective analysis, we assessed characteristics and survival rates of unresectable and/or metastatic pancreatic PDAC patients who started a systemic treatment between 01/2015 and 12/2021. Survival analyses were performed by Kaplan-Meier and Cox proportional hazards model. The number of 285 patients received at least two lines of treatment, but only 137 patients were suitable for third-line treatment. Subgroup analysis showed that thirty-seven patients received A line (gemcitabine/nab-paclitaxel or nab-paclitaxel combined therapy to FOLFIRINOX) therapy, 37 patients received B line (nab-paclitaxel combined therapy to gemcitabine combined therapy to FOLFIRINOX) therapy, 21 patients received C line (nab-paclitaxel combined therapy to gemcitabine combined therapy to oxaliplatin or irinotecan combined therapy) therapy. Survival rates for different treatment lines were significantly different and median overall survival (OS) was 14.00, 18.00, and 14.00 months, respectively (p<0.05). Our study provides real-world evidence for the effectiveness of different treatment sequences and underscores the treatment sequences on survival outcome when considering the entire management in advanced PDAC.